Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4677861 | 0.82 | CETP (0.33) | ARALDH1A1 | |
| SCHEMBL22769148 | 0.75 | IDO1 (0.47) | ARS1PR3SLC22A12ALDH1A1LMNA | |
| SCHEMBL27236967 | 0.67 | HDAC8 (0.46) | ARSLC22A12ALDH1A1LMNAGAA | |
| SCHEMBL16989778 | 0.67 | ALDH1A1 (0.46) | ALDH1A1LMNA | |
| SCHEMBL18677445 | 0.66 | IDO1 (0.51) | ARROCK2SLC22A12ALDH1A1LMNA | |
| SCHEMBL31053809 | 0.66 | AR (0.58) | ARIDO1 | |
| SCHEMBL2481947 | 0.66 | AR (0.61) | ARIDO1 | |
| SCHEMBL12050119 | 0.66 | AR (0.58) | ARIDO1 | |
| SCHEMBL16722682 | 0.66 | IDO1 (0.60) | ARS1PR3SLC22A12ALDH1A1LMNA | |
| SCHEMBL16728601 | 0.65 | ALDH1A1 (0.63) | ARSLC22A12ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2024-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NR5A1, NCOA1, NR5A2 | AR 4/4885ROCK2 4083/4885S1PR3 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.